About AHC
We are Aerodigestive Health Corporation (AHC), a "One Health" MedTech company advancing aerodigestive health through game-changing innovations for humans and animals.
Our company originated from Lever Scientific LLC, which we established in 2013 to bring Dr. Teresa Lever’s leading-edge research and technologies to market. As our portfolio grew—including the successful launch of FluoroKennel—we recognized the need for a broader organization to manage and accelerate these advancements. In 2023, we incorporated AHC as a Delaware C Corporation, building on Lever Scientific’s legacy to develop impactful solutions in aerodigestive health.
We employ a collaborative approach, partnering with leading academic institutions for development, testing, and validation. By launching service companies and product lines, we continuously refine our innovations and assess their commercial potential. Through strategic partnerships, sublicensing, and direct product sales, we are actively working to bring our solutions to a global market.
Driven by a commitment to precision and lasting impact, we focus on building strong relationships with partners and stakeholders to ensure our innovations achieve widespread adoption and deliver meaningful benefits—especially to the people and animals who most desperately need them.
AHC's mission is to advance aerodigestive health for humans and animals through precision, game-changing innovations.
Dr. Teresa Lever: Shaping Aerodigestive Health
Dr. Teresa Lever is an internationally recognized expert in swallowing and aerodigestive disorders, with significant contributions to research, clinical innovation, and commercialization in this field. Her expertise is most prominent in the intersection of digestive and respiratory health, especially as it relates to neurological disease. As a clinician-scientist and Professor of Otolaryngology at the University of Missouri School of Medicine, she has established herself as a leading voice in advancing our understanding and treatment of aerodigestive health disorders.
With over 20 years of clinical experience in speech-language pathology, Dr. Lever has dedicated her career to improving patient outcomes in adult-onset neurological disorders such as ALS, Parkinson’s disease, and stroke. Her research spans basic science, veterinary medicine, and clinical studies, embracing a "One Health" approach that bridges human and animal health. Dr. Lever's scientific impact extends worldwide through her publications and collaborations.
Key Achievements
-
Innovative Technologies: Dr. Lever has developed and patented several tools and methods to objectively quantify aerodigestive tract functions across species. These innovations are being used in numerous animal and human studies to enhance diagnostic accuracy and treatment efficacy.
-
Interdisciplinary Research: Funded by grants from the National Institutes of Health (NIH) and National Science Foundation (NSF), Dr. Lever collaborates with researchers from various fields, including respiratory physiology, engineering, neurology, otolaryngology, and radiology, to address the complex challenges of dysphagia.
-
Translational Impact: Her research focuses on translating biomedical innovations into clinician-friendly diagnostic and treatment tools. This includes adapting treatments proven effective in animal models for use in human clinical trials, aiming to improve the quality of life for individuals with dysphagia.
-
Awards and Recognition: Dr. Lever has received several awards for her research excellence, including the MU Top Faculty Achievers Award and the Excellence in Research Mentoring of Trainees Award.
Legacy and Impact
As a respected authority in her field, Dr. Lever's work has laid the foundation for Aerodigestive Health Corporation (AHC), a company dedicated to advancing aerodigestive health through innovative technologies. Her vision and contributions continue to inspire and guide AHC's mission to enhance diagnostic accuracy, treatment efficacy, and patient outcomes for humans and animals.
AHC Leadership Team
AHC's leadership team brings together a wealth of experience and expertise in aerodigestive health innovation.
Our team is further strengthened by a multi-disciplinary group of professionals including researchers, clinicians, and scientists alongside industry professionals and advisors experienced in commercializing innovations, launching new technologies, and successfully running businesses. Their combined expertise accelerates our path to market.